Artwork

Content provided by Chuck Shute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Chuck Shute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

Dr. Matthew W. Johnson and Using Psychedelics to Treat PTSD, Addiction & More

1:14:19
 
Distribuie
 

Manage episode 439819285 series 2763701
Content provided by Chuck Shute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Chuck Shute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Matthew W. Johnson, PhD, is a senior researcher for the Center of Excellence for Psilocybin Research and Treatment at Sheppard Pratt’s Institute for Advanced Diagnostics and Therapeutics. He is one of the world’s most accomplished scientists on the human effects of psychedelics and has conducted seminal research in the behavioral economics of drug use, addiction, and risk behavior. The conversation explores the evolution and impact of psychedelic research, particularly psilocybin and ketamine, over the past 20 years. Dr. Johnson highlights the shift from psilocybin's political casualty status to a multi-billion-dollar industry with FDA approval potential. Psilocybin shows promise in treating tobacco addiction, with a recent study doubling nicotine patch success rates. Ketamine, approved for depression, also shows potential in addiction treatment. The discussion touches on the therapeutic settings, the importance of preparation, and the potential for psychedelics to induce profound, lasting behavioral changes. The conversation also addresses the legal landscape, ethical considerations, and the risks associated with psychedelic use.
0:00:00 - Intro
0:00:13 - Interest in Psychedelics and Early Research
0:03:09 - Behavioral Science & Psychedelics
0:05:20 - MK Ultra and Mind Manipulation
0:07:58 - Therapeutic Setting and Regulation
0:10:07 - Comparison with Traditional Treatments
0:13:19 - Psychedelic Therapy Model
0:16:45 - Music and Environment
0:18:44 - Personal Reactions and Screening
0:23:15 - Neuroplasticity and Brain Changes
0:30:27 - PTSD and MDMA
0:33:15 - Ketamine & Addiction
0:51:20 - Realizations Under Psychedelics
0:56:20 - Prince Harry & Psychedelics
0:59:15 - Psychosis Risk & Vulnerability
1:03:05 - Pursuing Psychedelics Use & Legality
1:14:01 - Outro
Dr. Matthew W. Johnson link:
https://www.sheppardpratt.org/why-sheppard-pratt/our-experts/details/matthew-w-johnson-phd/
Chuck Shute link tree:
https://linktr.ee/chuck_shute

Support the show

Thanks for Listening & Shute for the Moon!

  continue reading

467 episoade

Artwork
iconDistribuie
 
Manage episode 439819285 series 2763701
Content provided by Chuck Shute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Chuck Shute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Matthew W. Johnson, PhD, is a senior researcher for the Center of Excellence for Psilocybin Research and Treatment at Sheppard Pratt’s Institute for Advanced Diagnostics and Therapeutics. He is one of the world’s most accomplished scientists on the human effects of psychedelics and has conducted seminal research in the behavioral economics of drug use, addiction, and risk behavior. The conversation explores the evolution and impact of psychedelic research, particularly psilocybin and ketamine, over the past 20 years. Dr. Johnson highlights the shift from psilocybin's political casualty status to a multi-billion-dollar industry with FDA approval potential. Psilocybin shows promise in treating tobacco addiction, with a recent study doubling nicotine patch success rates. Ketamine, approved for depression, also shows potential in addiction treatment. The discussion touches on the therapeutic settings, the importance of preparation, and the potential for psychedelics to induce profound, lasting behavioral changes. The conversation also addresses the legal landscape, ethical considerations, and the risks associated with psychedelic use.
0:00:00 - Intro
0:00:13 - Interest in Psychedelics and Early Research
0:03:09 - Behavioral Science & Psychedelics
0:05:20 - MK Ultra and Mind Manipulation
0:07:58 - Therapeutic Setting and Regulation
0:10:07 - Comparison with Traditional Treatments
0:13:19 - Psychedelic Therapy Model
0:16:45 - Music and Environment
0:18:44 - Personal Reactions and Screening
0:23:15 - Neuroplasticity and Brain Changes
0:30:27 - PTSD and MDMA
0:33:15 - Ketamine & Addiction
0:51:20 - Realizations Under Psychedelics
0:56:20 - Prince Harry & Psychedelics
0:59:15 - Psychosis Risk & Vulnerability
1:03:05 - Pursuing Psychedelics Use & Legality
1:14:01 - Outro
Dr. Matthew W. Johnson link:
https://www.sheppardpratt.org/why-sheppard-pratt/our-experts/details/matthew-w-johnson-phd/
Chuck Shute link tree:
https://linktr.ee/chuck_shute

Support the show

Thanks for Listening & Shute for the Moon!

  continue reading

467 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință